TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in December

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 57,600 shares, an increase of 22.8% from the November 30th total of 46,900 shares. Approximately 1.7% of the company’s stock are sold short. Based on an average trading volume of 35,900 shares, the short-interest ratio is currently 1.6 days.

Insider Buying and Selling

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the stock in a transaction dated Tuesday, December 17th. The shares were acquired at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the acquisition, the insider now directly owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders acquired 70,012 shares of company stock valued at $281,235. Corporate insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences in the second quarter valued at about $1,184,000. Duquesne Family Office LLC lifted its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares in the last quarter. Geode Capital Management LLC boosted its position in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at $240,000. Finally, MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at $184,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TLSI has been the subject of several recent research reports. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price for the company. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 target price on the stock. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Finally, Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI traded down $0.15 during midday trading on Friday, reaching $4.84. 57,126 shares of the company’s stock were exchanged, compared to its average volume of 39,959. The company’s 50 day simple moving average is $4.17 and its two-hundred day simple moving average is $4.86. The firm has a market capitalization of $147.59 million, a PE ratio of -1.94 and a beta of 0.56. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.